
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is positioned for substantial topline growth due to potential upfront and milestone payments, along with future recurring royalties stemming from its innovative blood tests developed through the Nucleosomics platform. The recent co-marketing agreement is expected to enhance the customer base for its Nu.Q Discover services, thereby increasing market penetration and revenue opportunities. Additionally, the strategic partnership with the Immunoassay Technology Center of Werfen, including exclusive commercial option rights, further solidifies Volition's foothold in the diagnostics market, potentially leading to significant financial gains.
Bears say
VolitionRX faces significant operational risks that could adversely impact its financial performance, including potential failures in the clinical development of diagnostic products and challenges in securing necessary licensing agreements. Additionally, the company's struggle to achieve market traction with its diagnostic offerings, alongside the risks of dilution and going concern issues, raise further concerns about its financial stability. These factors collectively contribute to a negative outlook for VolitionRX's stock as the company navigates a competitive and uncertain market environment.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares